Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.

Also called NCT01215097

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 306 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01215097
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Malaysia, Philippines (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01215097. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2013-06-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Linagliptin
Intervention (Drug)
placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01215097
Content hash
c2878e9e40166ff585b4c91b1afd82fa99e8f12b574a67e49448cc97f7a2a978